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Abstract: Postoperative nausea and vomiting (PONV) remains a signiﬁ  cant problem in 
modern anesthetic practice, with an incidence in high-risk groups of up to 80%. In addition to 
being unpleasant and distressing for the patient, PONV has the potential to adversely affect 
patient and surgical outcomes. Advances in PONV prophylaxis over recent years include using 
non-pharmacological means to reduce baseline risk, a change to less emetogenic anesthetic 
techniques and the combination of multiple antiemetic drugs. The 5-hydroxytryptamine-3 
(5-HT3) antagonists have proven a particularly valuable addition to the armamentarium against 
PONV. Palonosetron is a second-generation 5-HT3 antagonist that has recently been approved 
for prophylaxis against PONV. It has unique structural, pharmacological and clinical properties 
that distinguish it from other agents in its class. This review summarizes current evidence on 
PONV prophylaxis, reviews the 5-HT3 antagonists in particular and focuses on the established 
and future roles of palonosetron.
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Management of postoperative nausea 
and vomiting: an overview
Postoperative nausea and vomiting (PONV) is the most common complication of 
surgery and anesthesia. Both health care professionals and patients rate its avoidance 
and control of similar importance to that of alleviating pain.1–4 In addition to patient 
dissatisfaction,5 PONV may have adverse consequences such as delayed recovery, 
unexpected hospital admission and delayed return to work of ambulatory patients. 
Rarely postsurgical morbidities such as wound dehiscence, pulmonary aspiration, 
surgical site bleeding and dehydration occur.6 Nausea occurs in approximately 20% 
of patients in the recovery room and in 50% thereafter, with vomiting in 5% and 25% 
respectively.7 Although children more than 3 years of age are at higher risk than adults,8 
in some high-risk adult populations the incidence of PONV is 80% or more.9,10
It is difﬁ  cult to quantify the risk of PONV for any individual patient both because 
of the many pre-, intra- and postoperative factors that contribute to PONV and 
uncertainty about the relative impact of these potential inﬂ  uences. Activation of 
the vomiting center or the sensation of nausea may result from stimulation of the 
chemoreceptor trigger zone (eg, drugs, metabolic stimuli), the vestibular apparatus 
(motion), visceral afferent inputs (eg, gut distension or stasis, surgical stimulation 
of viscera, cardiovascular disturbance) and cortical inputs (eg, anxiety, pain, 
hypoxia, sensory stimuli, psychological associations, raised intracranial pressure). 
At least 3 nerves and 7 neurotransmitters are involved, making prophylaxis and 
treatment complex. In general a number of patient, surgical and anesthetic factors 
affect the risk of PONV6 and various patient risk assessment scores have been 
developed. The best known and validated is a simple 4-point score based mainly on 
patient characteristics. These are female gender, non-smoking habit, past history of Therapeutics and Clinical Risk Management 2009:5 22
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motion induced or postsurgical nausea and vomiting, and 
postoperative opioid requirement.11,12 Prediction of outcome 
in the individual patient is imperfect, but management 
based on risk stratiﬁ  cation of surgical sub-populations can 
reduce overall institutional rates of PONV.13,14 The duration 
of surgery (and anesthesia) is also a risk factor and some 
surgical procedures (eg, laparoscopy, strabismus surgery) 
are thought to confer higher risk, especially for nausea.15,16 
Other established factors are younger patient age,6,16 higher 
intra- and postoperative opioid requirement6,17 and the type 
of anesthetic. Regional anesthesia is associated with a much 
lower risk than general anesthesia,16 with signiﬁ  cant risk 
factors for the latter being maintenance with volatile agents 
rather than propofol,18 use of nitrous oxide19–21 and inadequate 
intravenous ﬂ  uid loading.22–24
Universal pharmacological prophylaxis against PONV 
is not warranted.25,26 If 30 of 100 people would feel sick or 
vomit after surgery and all 100 were given a prophylactic 
antiemetic drug, 10 would beneﬁ  t and 90 would not, and 
1 to 5 would suffer a mild side effect such as headache or 
sedation.27 Therefore non-pharmacological strategies to 
reduce the baseline risk of PONV should be considered. 
Level I evidence supports techniques such as acupuncture, 
acustimulation or acupressure from wrist-bands applied at 
the Chinese P6 (Neiguan or Nei-Kuan) point near the wrist 
or at a number of Korean acupressure points on the ﬁ  ngers. 
These produce up to a one-third reduction in PONV, making 
them more effective than ondansetron against nausea, and 
they have an excellent side effect proﬁ  le.28–30 Avoidance 
of general anesthesia or minimizing opioid requirement 
through the use of regional anesthesia might be appropriate,16 
intravenous ﬂ  uid (eg, 2 mL/kg for each hour of fasting) can be 
considered in ambulatory and high-risk inpatients,24 nitrous 
oxide avoided,19,20 and propofol used for both induction 
and maintenance of general anesthesia (reciprocal of the 
absolute risk reduction or number-needed-to-treat [NNT] 
of 5 to prevent PONV within 6 hours of surgery).18 Using 
total intravenous anesthesia is as effective as giving a single 
antiemetic such as ondansetron.19,31 In addition a multimodal 
analgesic regimen should be used to minimize opioid dose 
requirements.17
The cost-beneﬁ  t analysis of providing prophylaxis (rather 
than treatment) of PONV with antiemetic drugs is determined 
by the efﬁ  cacy of the drug, its cost, and the consequences 
of the event. If the baseline risk is high, pharmacological 
intervention with a multimodal approach is justiﬁ  ed.32,33 
Approximately 20 drugs show efﬁ  cacy, although only about 
8 drugs are of proven reliability.27 Of these, there is little 
evidence that any one is better than another and most have 
a NNT of 4 to 7. This means, for example, that a reduction 
in risk of PONV from 80% to 60% represents a 25% relative 
risk reduction and a 20% absolute risk reduction or NNT 
of 5. When the baseline risk is only 10% a similar relative 
risk reduction produces an absolute risk reduction of only 
2.5% and a NNT of 40.
Interventions that have proven ineffective for prophy-
laxis of PONV include ginger root and the cannabinoids,34,35 
while intravenous (iv) metoclopramide 10 mg shows poor 
efﬁ  cacy (no anti-nausea effect and NNT to prevent vomit-
ing of 10).36,37 The antihistamine and phenothiazine drug 
classes (eg, promethazine 12.5–25 mg iv, dimenhydrinate 
25–50 mg iv, prochlorperazine 5–12.5 mg iv, cyclizine 
50 mg iv) show efﬁ  cacy but clinical utility is limited, particu-
larly in ambulatory surgical patients, because of sedation.38–43 
Similar problems beset transdermal scopolamine44 which 
also requires application at least four hours pre-operatively 
due to its slow onset. Side effects such as visual disturbance 
(number-needed-to-harm [NNH] of 5), dry mouth (NNH 12), 
dizziness (NNH 50) and agitation (NNH 100) tend to persist 
and limit its value, particularly in the elderly.
The butyrophenone droperidol remains the most cost 
effective drug for the prophylaxis of PONV in adults,45–49 
despite recent issues relating to a ‘Black Box’ regulatory 
warning from the US Federal Drug Administration (FDA) 
in relation to possible cardiac conduction delay. It is cheap, 
has an NNT of 5 for both nausea and vomiting (NNT of 3 
when added to patient-controlled intravenous morphine), with 
administration at the end of prolonged surgery recommended 
because of its short duration of action. Droperidol is one of the 
few antiemetic drugs to show a dose-response relationship.27 
Low doses (500 μg to 1.25 mg) are effective and minimize 
sedative and extrapyramidal side effects, both of which can 
be worrisome for children and ambulatory surgical patients.50 
Cardiovascular events are extremely unlikely, because QT 
prolongation in the antiemetic dose range is not signiﬁ  cant,51,52 
and as such its FDA warning has now been downgraded.
Dexamethasone 4 to 5 mg iv is a cheap, long acting 
antiemetic drug that shows efﬁ  cacy against both nausea and 
vomiting (NNT 4).53–55 Early administration is recommended 
because it can prevent both early and late (up to 24 hours) 
PONV. After a single dose, dexamethasone appears to have 
an excellent side effect proﬁ  le, although its effects on immune 
function, and the potential for adverse outcomes such as 
wound infection, have not been studied.
The 5-hydroxytryptamine-3 (5HT3) receptor antagonists 
are popular prophylactic drugs and are considered in more Therapeutics and Clinical Risk Management 2009:5 23
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detail in the next section. The neurokinin-1 (NK1) receptor 
antagonists (aprepitant, rolapitant and casopitant) have an 
established indication for the prevention of chemotherapy-
induced nausea and vomiting and are now also undergoing 
evaluation for PONV. These drugs appear particularly useful 
in preventing emesis. Aprepitant has recently been approved 
by the FDA for prophylaxis of PONV and preoperative oral 
aprepitant 40 mg has greater efﬁ  cacy than ondansetron 4 mg 
IV against vomiting.56
Patients thought to be at moderate or high risk of PONV 
should receive multimodal prophylaxis57,58 that includes 2 or 
3 antiemetic drugs from different drug classes. Each drug is 
likely to result in a similar relative risk reduction, giving an 
additive but declining absolute effect.19 Many studies conﬁ  rm 
the value of combining two or more antiemetic drugs and this 
has led to the propagation of evidence-based guidelines.59–64 
Nevertheless, data on optimal dose combinations are scarce and 
lower doses than used for monotherapy may be effective.65
The treatment of established PONV should be modiﬁ  ed 
based on previous preventative measures and prophylactic 
drug therapies. Before management with antiemetic drugs, 
it may be possible to reduce symptoms by changing to an 
alternative analgesic or by adding adjuncts that reduce opioid 
dose consumption.66 Surgical, mechanical or incidental causes 
of nausea and emesis should also be excluded. If the patient 
has not received prophylactic antiemetic drugs, many of these 
drugs will show efﬁ  cacy as treatment at lower dosage than 
when used for prophylaxis (eg, iv ondansetron 1 mg or iv 
promethazine 6.25 mg).67,68 In general a rescue dose with a 
drug of the same class should not be given within 6 hours, 
and dexamethasone or scopolamine should not be repeated.62 
Although potentially effective in some circumstances,69,70 
sedative and anxiolytic drugs such as midazolam (1–2 mg 
and then 1–2 mg/h) or propofol (15–20 mg and then 15–20 
μg/kg/min) are infrequently used for prophylaxis. However, 
they offer valuable treatment options71–73 and are as 
efﬁ  cacious as iv ondansetron.70,73 If PONV appears speciﬁ  -
cally opioid-induced, low-dose naloxone (eg, 0.25 μg/kg/h) 
is also effective, without reversing analgesia.74
5-hydroxytryptamine antagonists 
in the management of PONV
The potential value of 5-hydroxytryptamine (serotonin) 
receptor antagonists was discovered through the study 
of metoclopramide in the 1980s. The finding that, at 
high doses, metoclopramide showed activity at serotonin 
‘M’ receptors (now known as 5-hydroxytryptamine 
type 3 [5-HT3] receptors) led to the development of speciﬁ  c 
receptor antagonists. Ondansetron was the ﬁ  rst drug to 
become commercially available for PONV and has been 
followed by many others, including granisetron, dolasetron, 
tropisetron, ramosetron, azasetron and palonosetron. The 
5-HT3 antagonists compare favorably with other antiemetic 
drugs,75 showing a NNT of 5 to 6 for prophylaxis against 
vomiting and 6 to 7 against nausea.67,76 Their efﬁ  cacy is 
similar to droperidol or dexamethasone for the prevention 
of vomiting in adults,19 and their favorable side-effect proﬁ  le 
has made them a popular choice in both adult and pediatric 
surgical populations. Because each of the 5-HT3 antagonists 
shows a generally similar efﬁ  cacy and side effect proﬁ  le, 
the choice of drug is often governed by local availability 
and cost considerations.77–80 However knowledge of the 
differences in their pharmacokinetics, receptor afﬁ  nity and 
pharmacogenetically-inﬂ  uenced responses allows a more 
objective approach to drug selection.
Mechanism of action
5-HT3 receptors are found in the gut and in areas of the central 
nervous system associated with the regulation of nausea and 
vomiting, being abundant in the chemoreceptor trigger zone 
of the area postrema81,82 which has projections to the vomiting 
center located in the lateral reticular formation of the medulla 
oblongata. Stimulation of these receptors initiates the 
vomiting reﬂ  ex.83 Peripheral 5-HT3 receptors are located in 
vagal nerve terminals, which are linked to the vomiting center 
via the nucleus tractus solitarius.83 Competitive antagonism 
with 5-HT3 receptor antagonists at these sites, and probably 
others, can block initiation of the vomiting reﬂ  ex caused by 
emetogenic stimuli.
Pharmacokinetics
Azasetron (Serotone®, Yoshitomi Pharmaceuticals) is licensed 
for PONV in Japan and Argentina. It is a benzamine derivative 
which exhibits potent and selective 5-HT3 receptor antagonism. 
It has a terminal half-life of 6 to 8 hours and 60% to 70% of 
the active drug is excreted unchanged in the urine.84
Dolasetron (Anzemet®, Sanoﬁ  -Aventis) is a prodrug that is 
rapidly metabolized by carbonyl reductase (elimination half-
life [t1/2β] less than 10 minutes) to the active form hydrolosetron. 
Hydrolosetron (t1/2β 7 hours) is predominantly metabolized in 
the liver via the cytochrome P450 enzyme CYP2D6. Hydrolos-
etron is mainly (53%) excreted unchanged in the urine.85
Granisetron (Kytril®, Roche) is unique among the 5-HT3 
antagonists in that its liver metabolism is by the cytochrome 
P450 CYP3A isoenzyme. Its t1/2β is 5–8 hours, and 12% is 
excreted unchanged in the urine.86Therapeutics and Clinical Risk Management 2009:5 24
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Ondansetron (Zofran®, GlaxoSmithKline) has a relatively 
short t1/2β (3–5 hours) and undergoes extensive liver 
metabolism, primarily via the CYP3A4 isoenzyme, although 
CYP2D6 is an important secondary pathway. Some of its 
metabolites exhibit pharmacological activity but their plasma 
concentrations are too low to be clinically important. Five 
percent is excreted unchanged in the urine.87
Ramosetron (Nasea®, Astella Pharma) is licensed for 
use in Japan and Thailand, and has an additional indication 
for treatment of irritable bowel disease. It has a t1/2β of 4 to 
9 hours, but a high receptor afﬁ  nity prolongs its duration of 
action.88
Tropisetron (Navoban®, Novartis) undergoes extensive 
liver metabolism by the CYP2D6 isoenzyme. Its t1/2β is 
8 hours, and 8% is excreted unchanged in the urine.89
Pharmacodynamics
The duration of therapeutic effect of the various 5-HT3 
antagonists is inﬂ  uenced by factors other than the elimination 
half-life, and appears more closely associated with their 
binding afﬁ  nity for the 5-HT3 receptor.90 Skin-ﬂ  are testing, 
in which inhibition of cutaneous 5-HT3 receptors is used as 
a surrogate marker, shows that some drugs have a longer 
clinical effect than their elimination half-life might suggest. 
For example cutaneous 5-HT3 inhibition lasts 9 hours after 
ondansetron and more than 24 hours after a single intravenous 
dose (40 μg/kg) of granisetron.91 This probably reﬂ  ects 
granisetron’s high receptor afﬁ  nity, demonstrated in vitro by 
the displacement of ondansetron but not granisetron by high 
receptor concentrations of 5-HT. Other 5-HT3 antagonists 
with insurmountable receptor binding are tropisetron and 
palonosetron.92,93 Half-lives and receptor afﬁ  nities for the 
various 5-HT3 antagonists are shown in Table 1.
Pharmacogenetics
Various genetic factors inﬂ  uence an individual’s response 
to drugs and genetic polymorphism plays a role in the 
metabolism, transport and receptor binding of the 5-HT3 
antagonists.
CYP2D6 genetic polymorphism
Phase I metabolism of the 5-HT3 antagonists occurs in the 
liver by the cytochrome P450 enzyme system, the most 
important isoenzyme for which is cytochrome P4502D6 
(CYP2D6). This isoenzyme is responsible for the metabolism 
of many drugs94 and there is signiﬁ  cant inter-individual 
variability in its activity. The gene encoding CYP2D6 lies on 
chromosome 22q13.195,96 and gene variants can alter enzymic 
activity, such that individuals can be classiﬁ  ed as poor, 
intermediate, extensive and ultra-rapid metabolizers. Most 
of the population have the ‘wild-type’ 2D6 allele and are 
extensive (normal) metabolizers.97 Ultrarapid metabolizers 
typically display gene duplications and the resultant increase 
in enzyme activity may lead to sub-therapeutic plasma 
concentrations despite usual doses.98 Ethnic variability in 
the prevalence of ultra-rapid metabolizers is pronounced, 
varying from a low incidence in Caucasians (2%), 7% in 
parts of Spain (possibly due to Moorish colonization prior 
to the 15th century), to 20% to 29% in Arabic countries and 
Ethiopia.94,99–101
Although the CYP2D6 system is the dominant metabolic 
pathway for the 5-HT3 antagonists such as dolasetron, 
tropisetron and palonosetron, it is less influential for 
ondansetron which is primarily metabolized by CYP3A4. 
Granisetron’s metabolism is entirely independent of 
CYP2D6, undergoing transformation by CYP3A (Table 2). 
Table 1 Half-lives and 5-HT3 receptor binding afﬁ  nity for 5-HT3 
antagonists
Drug Binding afﬁ  nity (pKi) Half-life in healthy 
adult volunteers (h)
Azasetron No data 6–8
Dolasetrona 9.8b 6.9–7.3
Granisetron 8.42 4.9–7.7
Ondansetron 8.07 3.5–5.5
Ramosetron 8.5–9.0b 4.3–9.0
Tropisetron 8.81 8
Palonosetron 10.4 40
aValues are those of the active metabolite hydrolosetron.
bAntagonist afﬁ  nity (pA2).
Table 2 Metabolism of 5-HT3 antagonists
Drug Primary pathway Secondary pathway
Dolasetrona CYP2D6 CYP3A
Granisetron CYP3A CYP3A4
Ondansetron CYP3A4 CYP1A2
CYP2D6
CYP2E1
Ramosetron CYP1A2 CYP2D6
CYP141
Tropisetron CYP2D6 CYP3A4
CYP2E1
Palonosetron CYP2D6 CYP3A4
CYP1A2
aValues are those for the active metabolite hydrolosetron.Therapeutics and Clinical Risk Management 2009:5 25
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Genetic polymorphisms of CYP2D6 can inﬂ  uence clinical 
efficacy. Higher rates of vomiting occur in ultrarapid 
metabolizers treated with tropisetron (and to a lesser extent 
ondansetron) than in extensive or poor metabolizers.102,103 In 
contrast granisetron is unaffected by ultrarapid metabolizer 
status, and despite palonosetron undergoing CYP2D6 
metabolism a small study found no difference in efﬁ  cacy 
between poor and extensive metabolizers (although no 
ultrarapid metabolizers were investigated).90 Genetic testing 
may identify individuals who are less likely to respond to 
certain 5-HT3 antagonists, but screening is only likely to be 
helpful in high-risk ethnic populations.98
5-HT3 receptor genetic polymorphism
The 5-HT3 receptor is a ligand-gated cation channel with 
a pentameric structure. Five subunits enclose an ionopore 
modulating passage of ions such as calcium when activated 
by binding of serotonin. A number of polymorphisms of 
the gene coding for the 5-HT3B subunit exist, and oncology 
patients who are homozygous for an AAG deletion have a 
poorer response to tropisetron and ondansetron.104 The extent 
to which receptor polymorphism inﬂ  uences the efﬁ  cacy 
of other 5-HT3 antagonists remains unclear, another study 
finding no difference in the antiemetic efficacy among 
patients with different polymorphisms of the 5-HT3A receptor 
subunit.105
ABCB1 transporter genetic polymorphism
The adenosine triphosphate-binding cassette subfamily 
B member 1 (ABCB1) transporter (also known as P-glycoprotein 
or MDR-1) functions as a transmembrane efﬂ  ux pump in many 
tissues. It is responsible for the physiological transportation of 
a variety of drugs, including the 5-HT3 antagonists. A single-
nucleotide polymorphism at position 3435 of the ABCB1 gene 
has shown limited inﬂ  uence on 5-HT3 antagonist efﬁ  cacy. 
One study of granisetron, ondansetron and tropisetron found 
improved short-term (with a trend towards long-term) efﬁ  cacy 
of granisetron in ABCB1 3435 TT individuals compared 
to ABCB1 3435 CC or CT genotypes.106 This ﬁ  nding may 
reﬂ  ect higher CNS levels of granisetron due to improved drug 
transport, but further studies are required.
Clinical efﬁ  cacy
The anti-vomiting effect of this class of drugs is greater than 
the anti-nausea effect76 and there is a 25% overall risk reduction 
for PONV.19,67 This makes the 5-HT3 antagonists cost effective 
for prophylaxis in high-risk patients, and although droperidol 
is cheaper and equally effective in adults, ondansetron prevents 
vomiting more effectively in children.37
The maximum recommended doses for single drug 
prophylaxis are 8 mg iv or 16 mg orally for ondansetron,107 
12.5 mg IV for dolasetron,108,109 1 mg iv for granisetron110 
and 5 mg iv for tropisetron.111 If the patient has not received 
prophylaxis a smaller iv dose (eg, ondansetron 1 mg, 
granisetron 0.1 mg or tropisetron 0.5 mg) is recommended 
for treatment.63,67 The NNT to prevent another episode of 
nausea or vomiting within 24 hours is 4 to 5.112
Adverse effects
The 5-HT3 antagonists have an enviable safety profile, 
with most side effects (eg, headache, constipation and 
asthenia) mild and transient. The NNH for ondansetron is 
36 for headache, 31 for elevated liver enzymes and 23 for 
constipation.76
The cardiovascular and ECG effects are of particular 
interest since the saga of the (now reversed) FDA “Black 
Box” warning about droperidol and cardiac risk due to 
prolongation of the QT interval. All 5-HT3 antagonists 
block cardiac sodium ion channels in vitro113 and thus have 
the potential to alter cardiac conduction. Safety studies 
in healthy volunteers indicate a transient increase in PR, 
QRS and QTc intervals after dolasetron114 and prolonged 
QTc intervals after ondansetron,52 however a single dose 
of a 5-HT3 antagonist is considered unlikely to cause 
cardiovascular effects81 and meta-analysis shows mono-
therapy or combined therapy has a similar safety proﬁ  le to 
droperidol or dexamethasone.115
Palonosetron
Background
Palonosetron (Aloxi®, MGI Pharma) is the latest 5-HT3 
antagonist licensed and the only drug of its class approved for 
prophylaxis against both acute and delayed chemotherapy-
induced nausea and vomiting (CINV). Its unique properties 
have led to it being described as the ﬁ  rst of a ‘second-
generation’ of 5-HT3 antagonists. Far higher receptor afﬁ  nity 
and a much longer half-life than other 5-HT3 antagonists 
confer a prolonged duration of action. Following successful 
Phase III clinical trials the FDA approved its use for 
prevention of PONV in March 2008.
Chemical structure and binding
Traditional 5-HT3 antagonists are based on a 3-substituted 
indole ring which mimics the structure of serotonin. In 
contrast palonosetron is a single stereoisomer isoquinoline Therapeutics and Clinical Risk Management 2009:5 26
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based on a fused tricyclic ring system attached to a 
quinuclidine moiety (Figure 1). This novel chemical structure 
may explain some of the differences in its receptor afﬁ  nity, 
interaction and binding.
Pharmacokinetics
The pharmacokinetic profile of palonosetron has been 
evaluated in healthy volunteers116,117 and cancer patients.118 
A single dose of 10 μg/kg iv is widely distributed in the 
tissues (mean ± SD volume of distribution 8.3 ± 2.4 L/kg). 
Palonosetron is moderately bound to plasma proteins (62%)119 
and despite its extensive distribution, little is sequestered in 
erythrocytes.117
In keeping with most 5-HT3 antagonists, the metabolism 
of palonosetron is primarily in the liver by the cytochrome 
P450 enzyme system, with CYP2D6 the predominant 
isoenzyme and CYP3A4 and CYP1A2 of secondary 
importance.119 The main metabolites, N-oxide-palonosetron, 
6-(S)-hydroxy-palonosetron and small amounts of 6-keto-N-
oxo-palonosetron display less than 1% of palonosetron’s 
activity at 5-HT3 receptors.117 Although a small study (n = 6) 
comparing poor against extensive metabolizers of CYP2D6 
substrates found no difference in efﬁ  cacy,90,119 palonosetron 
has not been studied in ultrarapid metabolizers so it is 
possible that in this genotype it has reduced efﬁ  cacy.
Following initial rapid distribution, iv palonosetron 
undergoes a slow elimination phase, primarily handled by the 
kidney, with 83% of a 10 μg/kg dose being recovered from 
the urine after 240 hours117 and 40% of the administered dose 
excreted unchanged. Total body clearance of palonosetron 
in healthy subjects is approximately 160 ml/h/kg, with renal 
clearance approximately 66.5 mL/h/kg. This slow elimination 
results in a long terminal half-life of approximately 
40 hours,116,117 which contrasts with previous 5-HT3 
antagonists such as ondansetron (3–5 hours) and granisetron 
(5–8 hours) (see Table 1).
Pharmacokinetic studies show that the characteristics of 
palonosetron in healthy volunteers and elderly patients with 
cancer are similar116–118 and widespread clinical experience 
in the CINV setting conﬁ  rms that no dose adjustment is 
necessary in elderly patients.119,120 In addition, mild to 
moderate renal impairment or hepatic impairment do not 
affect its pharmacokinetic parameters and dose modiﬁ  cation 
is unnecessary.119
There is currently no clinical experience with palonosetron 
in pregnant or lactating women. Studies of teratogenicity in 
animal models show no evidence of interference with fertility 
or fetal development, but caution is advised until safety in 
these populations is established.119 There is little experience 
to date to determine the safety of palonosetron in children, 
however emerging evidence suggests that it is effective and 
appears safe.121
Pharmacodynamics
Receptor binding is thought to be the most important factor 
inﬂ  uencing the duration of action of the 5-HT3 antagonists. 
Palonosetron is structurally distinct
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First-generation 5-HT3 antagonists resemble serotonin
Palonosetron is structurally distinct
Palonosetron
N
N N
N N
H
O
N
N
H
H
H
H
O
O
O
O
O
N
N N
N
N
N
N
O
HO
HO
NH2
CH3
CH3
CH3
CH3
Figure 1 Structures of palonosetron and other 5-HT3 antagonists.
Reproduced with permission from Rojas C, Grunberg S, Rosti G. 2007. Creating real beneﬁ  t for patients at risk of nausea and vomiting: palonosetron-from bench to bedside. 
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Palonosetron shows avid binding to the 5-HT3 receptor, with 
a pKi of 10.4,93 which far exceeds other 5-HT3 antagonists. 
This binding afﬁ  nity is more than 30 times the potency of 
granisetron and 100 times that of ondansetron (Table 1). In 
addition, in isolated specimens binding is insurmountable 
by the addition of increasing concentrations of agonist, 
which suggests that palonosteron is not simply a com-
petitive antagonist at the 5-HT3 receptor.93 High receptor 
afﬁ  nity is accompanied by high selectivity, with low afﬁ  nity 
(pKi   6.0) demonstrated for various other receptors includ-
ing 5-HT1A,1D,2A,2C.93 This makes it unlikely that palonosetron 
will produce unwanted effects at other receptor sites.
Emerging evidence indicates that palonosetron interacts 
at the 5-HT3 receptor in a different manner to previous 5-HT3 
antagonists. The chemical structure is dissimilar to serotonin, 
so palonosetron may bind to the 5-HT3 receptor at an allosteric 
site, different to other antagonists that bind at the orthosteric 
site occupied by serotonin.122 This interaction at the alloste-
ric site may prevent attachment of serotonin at its orthosteric 
site, explaining the insurmountable binding noted in vitro. 
Furthermore studies of calcium inﬂ  ux in specimens exposed 
to and then washed clear of palonosetron show continued 
receptor occupation well beyond that predicted by controls and 
far in excess of that shown by granisetron and ondansetron.123 
The investigators ascribe this to possible internalization of the 
5-HT3 receptor following exposure to palonosetron.
Adverse effects
Side effects
Observation of side effects during the clinical development of 
palonosteron indicated a similar safety proﬁ  le to other 5-HT3 
antagonists, the most common side effects being non-serious 
and short duration headache (9%), constipation (5%) and 
dizziness (1%)119 (Table 3). Post-marketing surveillance data 
after over 1 million patient exposures conﬁ  rms of the safety 
of palonosetron, with few serious adverse events reported 
(n = 81, 0.0061%), most frequently headache (n = 13), 
hypersensitivity reactions (n = 8) and injection site burning 
or discomfort (n = 8).124
Cardiac conduction
The potential for a delay in cardiac conduction, in particular 
QTc prolongation, was evaluated in Phase III studies. In 
common with other 5-HT3 antagonists, palonosetron slightly 
increases QTc intervals, the mean increase after a bolus dose 
lying between 1 and 3 ms.125–127 This compares favorably with 
a 5 ms increase after ondansetron125,127 and a 5.4 ms increase 
after dolasetron.126 Palonosetron has been safely administered 
to many patients with cardiac impairment although the 
prescribing information advises caution in patients at risk 
of QTc prolongation.119
Drug interactions
Palonosetron does not cause inhibition or induction of the 
main hepatic enzyme systems including CYP2D6, CYP1A2 
and CYP3A4/5, so the risk of signiﬁ  cant drug interactions is 
low.119 However an adverse reaction with apomorphine that 
presented as profound hypotension and altered consciousness 
has been reported, so concomitant use is contraindicated.128
Therapeutic efﬁ  cacy
The following deﬁ  nitions have been used in trials describing 
palonosetron’s therapeutic efficacy: complete response 
(CR) – no rescue medication, no emesis; complete control 
(CC) – no rescue medication, no emesis, no more than mild 
nausea; treatment failure – episode of emesis, or rescue 
medication administered; early nausea and vomiting – 0 to 
24 hours; delayed nausea and vomiting −24 to 120 hours.
Chemotherapy-induced nausea and vomiting
Most clinical experience with palonosetron has been in the 
setting of the management of CINV, with over 5 million 
doses having been prescribed. For the purpose of this review, 
Table 3 Adverse reactions of palonosetron, ondansetron and dolasetron
Event Palonosetron 0.25 mg (n = 633) Ondansetron 32 mg (n = 410) Dolasetron 100 mg (n = 194)
Headache 60 (9%) 34 (8%) 32 (16%)
Constipation 29 (5%) 8 (2%) 12 (6%)
Diarrhea 8 (1%) 7 (2%) 4 (2%)
Dizziness 8 (1%) 9 (2%) 4 (2%)
Fatigue 3 ( 1%) 4 (1%) 4 (2%)
Abdominal pain 1 ( 1%) 2 ( 1%) 3 (2%)
Insomnia 1 ( 1%) 3 (1%) 3 (2%)
Data reproduced with permission from MGI Pharma.119Therapeutics and Clinical Risk Management 2009:5 28
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key outcomes only are described. In a phase II dose-ranging 
study118 complete response rates were highest in the 3 to 
90 μg/kg groups and there was no dose-related increase in 
side effects. Consequently 0.25 mg and 0.75 mg (equivalent 
to 3 and 10 μg/kg respectively) doses were evaluated in 
phase III trials as minimum effective doses. The recom-
mended initial treatment dose for CINV is now 0.25 mg.
For the control of early CINV (ie, 0–24 hours), 
phase III studies found that palonosetron compared favorably 
with dolasetron and ondansetron. Palonosetron 0.25 mg or 
0.75 mg or dolasetron 100 mg resulted in similar complete 
response rates of 63%, 57% and 53% respectively. However, 
the palonosetron 0.25 mg group had fewer episodes of 
emesis and more patients free of emesis compared with the 
dolasetron group.126 In a comparison of palonosetron 0.25 mg, 
0.75 mg or ondansetron 32 mg, palonosetron 0.25 mg was 
associated with a higher early complete response rate than 
ondansetron and fewer emetic episodes.125
In the 24–120 hour period palonosetron 0.25 mg and 
0.75 mg were superior to dolasetron 100 mg for complete 
response rates (54%, 57% and 39%, respectively) and for 
complete control (48%, 52% and 36%, respectively).126 
The complete control rates were higher with palonosetron 
on days 2 and 3 post administration and on day 4 after the 
higher dose. The number of patients free of nausea was also 
higher in both palonosetron groups and time to ﬁ  rst emetic 
episode or treatment failure was longer, with most patients 
not requiring rescue medication until more than 2 days after 
their single dose. Similar results were seen in the comparison 
with ondansetron 32 mg.125 A pooled analysis of these trials 
found early CINV was an important predictor for delayed 
CINV129 but that patients without early CINV receiving 
palonosetron were less likely to get delayed CINV compared 
with dolasetron and ondansetron. Conversely patients who 
experienced early CINV despite palonosetron were more 
likely to be protected against delayed CINV (23%) than 
those taking dolasetron or ondansetron (12%). Therefore, as 
well as showing early efﬁ  cacy, palonosetron seems to confer 
additional protection against delayed CINV.
Combination therapy using palonosetron with antiemetic 
drugs of other classes appears safe and effective.130 
Palonosetron 0.25 mg and dexamethasone 8 mg produced 
high early complete response rates (84%), falling to 59% 
for late CINV. Only 3% to 13% of patients complained 
of more than mild nausea during days 0 to 5. In one study 
comparing palonosetron with ondansetron the early complete 
response rate did not differ overall, but among those also 
given dexamethasone complete response rates were improved 
in the 24- to 120-hour period in the palonosetron group.127 
Triple therapy prophylaxis using aprepitant, dexamethasone 
and palonosetron 0.25 mg resulted in high rates of early 
efﬁ  cacy (complete response 88%, no emesis 93% and no 
nausea 71%). These beneﬁ  ts extended into the ‘delayed 
CINV’ period and only 0% to 5% of patients rated their 
nausea as severe.131 A double-blinded, placebo-controlled, 
randomized pilot study was terminated after an interim 
analysis showing unacceptable early and delayed CINV in 
patient groups receiving palonosetron and dexamethasone 
in whom aprepitant was not also given.132 Good efﬁ  cacy has 
been reported with this triple therapy combination given on 
day 1 only, the incidence of no emesis reported as 97% to 
100% over 5 days.133
Multiple-day dosing with palonosetron 0.25 mg on 
alternate days appears effective but has not been adequately 
evaluated compared with a single dose.134,135
Palonosetron for PONV
Optimum dosing
Two placebo-controlled randomized studies have evaluated 
palonosetron across a range of doses for prophylaxis against 
PONV. Three hundred and eighty-one women undergo-
ing major gynecological surgery were randomized to doses 
between 0.1 μg/kg and 30 μg/kg or placebo.136 1 μg/kg 
and 30 μg/kg doses produced a signiﬁ  cantly better complete 
response in the first 24 hours (44% (p = 0.004) and 
45% (p = 0.002) vs 19%) and a lower incidence of nausea 
during the same period. The second study compared 
0.025 mg, 0.05 mg, and 0.075 mg doses of palonosetron in 
546 patients with a simpliﬁ  ed Apfel risk score for PONV 
of  2  9,11 undergoing laparoscopic surgery.137 Only the 
highest 0.075 mg dose showed a signiﬁ  cantly improved 
rate of complete response compared with placebo in the 
0–6 hour, 0–24 hour and 0–72 hour periods (49% vs 37%; 
43% vs 26%; 39% vs 24% for each period respectively, 
p   0.05). Patients receiving 0.075 mg were also less likely 
to report functional interference (eg, with appetite, enjoy-
ment of life, social life) because of PONV experienced in 
the ﬁ  rst 24 hours. Based on these two studies, the minimum 
effective dose of palonosetron in the setting of PONV is 
0.075 mg, and this dose has been approved by the FDA for 
PONV prophylaxis.
Early PONV
Two identically designed multi-center double-blind 
placebo-controlled Phase III efﬁ  cacy trials were published 
recently.138,139 Both trials included early PONV amongst Therapeutics and Clinical Risk Management 2009:5 29
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their primary and secondary endpoints. In one study138 
544 patients who were at least a moderate risk of PONV 
(Apfel risk score   2) undergoing inpatient gynecologi-
cal or breast surgery were given palonosetron 0.025 mg, 
0.05 mg, 0.075 mg or placebo. All patients received nitrous 
oxide as part of their anesthetic and no other prophylactic 
antiemetic drugs. There was a dose-dependent increase in 
complete response in the 0-to 24-hour period, with rates for 
the placebo, palonosetron 0.025 mg, 0.05 mg and 0.075 mg 
groups being 36%, 46% (p = 0.073), 47% (p = 0.069) and 56% 
(p = 0.001), respectively (Figure 2). The incidence of emesis 
was signiﬁ  cantly reduced in the palonosetron 0.075 mg group 
compared with placebo (40.0% vs 60.3%, p = 0.001), as was 
the incidence of nausea (49.6% vs 70.6%, p = 0.001). The 
severity of nausea (graded as none, mild, moderate, severe) 
was lower with all three doses of palonosetron.
In the other study139 574 patients with Apfel score   2 and 
undergoing day-case laparoscopy received prophylaxis against 
PONV with palonosetron 0.025 mg, 0.05 mg, 0.075 mg or 
placebo. Nitrous oxide was used but no other prophylactic 
antiemetics were administered. A similar dose-dependent 
increase in complete response was observed, with rates in the 
0- to 24-hour period for the placebo, palonosetron 0.025 mg, 
0.05 mg and 0.075 mg groups of 26%, 33% (p = 0.187), 39% 
(p = 0.017) and 43% (p = 0.004), respectively (Figure 2). The 
incidence of early emesis was lower in the palonosetron 0.075 
mg group compared with placebo (33% vs 44%, p = 0.075), 
as was the severity of nausea (p = 0.036).
These studies confirm that palonosetron 0.075 mg 
provides effective prophylaxis against acute early PONV. 
The relative risk reduction of 20% to 30% is of a magnitude 
comparable to that with other single-agent interventions.140
Delayed PONV
Both the phase III studies detailed above also evaluated 
the incidence of PONV in the delayed (24- to 72-hour) and 
‘postdischarge’ (6- to 72-hour) periods. Kovac et al found 
complete response rates for placebo, palonosetron 0.025 mg, 
0.05 mg and 0.075 mg of 43%, 53%, 52% and 66% (p   0.05) 
respectively during the 6- to 72-hour period, and 52%, 56%, 
61% and 70% (p = 0.002), respectively, during the 24–to 
72-hour period138 (Figure 3). The time to treatment failure 
was signiﬁ  cantly prolonged in the palonosetron 0.075 mg 
group (p = 0.004), and the median time to ﬁ  rst emesis was 
more than 72 hours after palonosetron 0.05 mg (p = 0.014) 
and 0.075 mg (p = 0.002) (compared with 3.9 hours after 
placebo). The severity of nausea was less in the 6- to 72-hour 
period for the palonosetron 0.075 mg group (p = 0.011).
Complete response rates in the Candiotti et al study for pla-
cebo, palonosetron 0.025 mg, 0.05 mg and 0.075 mg were not 
signiﬁ  cantly different over the 24- to 72-hour period (Figure 3), 
and 34%, 38%, 39% and 45% (p = 0.064) respectively for 
the 6- to 24-hour period.139 The dose-dependent increase in 
complete response with increasing palonosetron dosage did 
not reach statistical signiﬁ  cance but was present with respect 
to delay of treatment failure. Although the incidence of late 
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Figure 2 0- to 24-hour PONV: complete response (CR), no nausea and no emesis.
*p   0.017; **p   0.05.
Data derived from Kovac et al 2008138 and Candiotti et al 2008.139
Abbreviations: Palo, palonosetron; PONV, postoperative nausea and vomiting.Therapeutics and Clinical Risk Management 2009:5 30
Muchatuta and Paech
52
90
41
91
56
44
61
47
70
96
49
91
0
10
20
30
40
50
60
70
80
90
100
CR No emesis CR No emesis
%
 
o
f
 
p
a
t
i
e
n
t
s
Placebo Palo 0.025 mg Palo 0.05 mg Palo 0.075 mg
*
Kovac et al Candiotti et al
Figure 3 24- to 72-hour PONV: complete response (CR) and no emesis.
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Data derived from Kovac et al 2008138 and Candiotti et al 2008.139
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emesis did not differ between the groups, there was a reduction 
in the intensity of nausea in the palonosetron 0.075 mg group 
for the 6- to 72-hour period (p = 0.036).
These ﬁ  ndings conﬁ  rm that palonosetron, at a dose of 
0.075 mg, improves the control of nausea and vomiting into 
the second and third days post operatively, an effect that may 
be most marked after major operations requiring inpatient 
stay. Palonosetron 0.075 mg also reduces the severity of 
delayed nausea, which may be of particular relevance to the 
day-surgery population for whom it is difﬁ  cult to identify 
those at risk of postdischarge PONV and for whom early 
return to normal activities is important.141 Of note, palono-
setron also seems to have a prolonged effect in reducing the 
severity of nausea, a feature not shared by other 5-HT3 antago-
nists. However the magnitude of effect against PONV appears 
to be similar to that of other established drugs following 
inpatient surgery in moderate- or high-risk groups, and mod-
est against delayed PONV in ambulatory surgical patients 
with shorter and lower postoperative opioid requirements, so 
more evidence is required before a role against postdischarge 
PONV in the day-care setting can be recommended.
Discussion
Approval of palonosetron for the prevention of PONV 
provides another therapeutic intervention in the arsenal 
against the ‘big little problem’.142 The prolonged half-life and 
very strong afﬁ  nity of palonosetron for the 5-HT3 receptor 
provide the pharmacological basis for a long duration of action 
that appears to far exceed that of other 5-HT3 antagonists. 
Clinical effectiveness into the ﬁ  fth day after chemotherapy has 
been demonstrated, and after surgery prolonged effectiveness 
is also of potential value because PONV often presents late or 
after discharge.141 Palonosetron is an established antiemetic 
drug in oncology medicine, where it shows better efﬁ  cacy 
against both early and delayed CINV than other 5-HT3 antago-
nists. This prolonged clinical effect combined with superior 
efﬁ  cacy against PONV mitigates a traditional obstacle for a 
newly developed drug – its cost. A recent theoretical evalu-
ation suggested its cost effectiveness compared favorably 
with ondansetron.143 However the etiology of CINV, which 
involves a large release of serotonin from the enterochromaf-
ﬁ  n cells in the small intestine in response to chemotherapeutic 
agents, is different to that of PONV, which has multi-factorial 
aetiology. It remains to be seen whether the same degree of 
efﬁ  cacy can be expected in the postsurgical setting.
The role of combination therapy in patients at high risk 
of PONV has been well established.19,57,58 On the basis of 
promising results for combination therapy with palonosetron 
in CINV, similar studies in the surgical population will no 
doubt be undertaken. The effectiveness of palonosetron and 
dexamethasone, particularly against nausea, may dovetail 
well with the antiemetic properties of the neurokinin-1 
antagonists such as aprepitant. Future research needs to be 
directed towards comparisons of the efﬁ  cacy of palonosetron Therapeutics and Clinical Risk Management 2009:5 31
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and other 5-HT3 antagonists, towards establishing suitable 
drug and drug dose combinations to prevent PONV in high-
risk patient groups (including cost-effectiveness evaluation). 
Investigation of its efﬁ  cacy for the treatment of PONV is also 
required. Although the clinical value of palonosetron in this 
setting has yet to be established, the pre-marketing evidence 
suggests it may be a valuable addition to the pharmacological 
armamentarium.
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